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ABSTRACT
The complex interaction between inflammatory mediators in allergic rhinitis (AR) is determined by the role 
of genetic polymorphisms, including interleukin (IL) and toll-like receptor (TLR) genes. This study aimed 
to discuss the effects of H1-antihistamines on IL and TLR systems. Several ILs involved in AR pathogene-
sis are: IL-4 (rs2243250, rs1800925, rs1801275, rs2227284, rs2070874), IL-6 (rs1800795, rs1800797), 
IL-10 (rs1800871, rs1800872), IL-12R (rs438421), IL-13 (rs1800925, rs20541), IL-17 (rs3819024), IL-18 
(rs360721, rs360718, rs360717, rs187238), IL-23R (rs7517847), and IL-27 (rs153109, rs17855750). In 
the IL system, histamines stimulate the IL production in Type 2 helper T (Th2) cells through protein kinase A 
(PKA), janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway, and the activation 
of H1-histamine receptor and histidine decarboxylase (HDC) genes. On contrary, antihistamines down-reg-
ulate the H1-histamine receptor gene expression through the transcription suppression of HDC and IL 
genes and suppress histamine basal signaling through the inverse agonistic activity. TLRs involved in AR 
pathogenesis are TLR2 (rs4696480, rs3804099, rs5743708), TLR4 (rs4986790), TLR6 (rs2381289), TLR7 
(rs179008, rs5935438), TRL8 (rs2407992, rs5741883, rs17256081, rs4830805, rs3788935, rs178998), 
and TLR10 (rs11466651). In the TLR system, histamines trigger the TLR expression by stimulating interfer-
on-γ (IFN-γ) to up-regulate mast cells and by stimulating receptor-interacting protein (RIP) to activate IκB 
kinase-β. Contrastingly, antihistamines suppress TIR-domain-containing adaptor protein inducing IFN-β 
(TRIF) and RIP protein and thus inhibit the expression of TLR. In addition, several studies indicated that 
H1-antihistamines inhibit the IL and TLR systems indirectly.
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INTRODUCTION
Allergic rhinitis (AR) is one of the most common 
allergic diseases. The incidence of AR is estimated 
between 10 to 25% of the world population. AR has 
been associated with the main reasons why people 
visit primary care (1). AR is not a life-threatening 
disease, but it can significantly impair the quality of 
life (2). Total funding issued to AR was estimated 
approximately 5.3 billion dollars per year (3). The 
incidence of AR in the United States (US) was esti-
mated approximately 40 million cases (4). Nihlen 
et al. (5) reported that the prevalence of AR was 
estimated around 15% in men and 14% in women. 
Several studies showed different results on the age 
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that is most susceptible to AR. Dykewics et al. (6) 
reported that approximately 80% of AR cases had 
developed the disease at the 20 years of age, while 
Settipane (7) reported that the prevalence of AR was 
about 40% higher in children.
AR is a disease characterized by four cardinal symp-
toms, including: itching, sneezing, rhinorrhea, and 
nasal congestion. AR is classified into intermittent 
and persistent rhinitis. The clinical manifestations of 
AR are caused by allergen exposure that triggers the 
immune response, and this process is reversible (1). 
Mucous membrane inflammation in AR is caused by 
complex interaction between inflammatory media-
tors and it is triggered by the response of immu-
noglobulin E (IgE) against extrinsic proteins (8). 
This process is determined by the variation in gene 
expression. Study by Mizuguchi et al. (9) showed 
that the variation in cytokine receptor genes and 
H1-histamine receptors played an important role in 
the pathogenesis of AR. Hussein et al. (10) showed 
that polymorphisms of Toll-like receptors 2 (TLR-2) 
and TLR-4 genes were associated with susceptibility 
to AR. Furthermore, Testa et al. (11) showed that 
the variation in interleukin 4 (IL-4) gene expression 
determined the severity of AR. In addition, the vari-
ation in ILs gene expression have also been associ-
ated with the severity of AR (12,13).
H1-antihistamines have been used extensively for the 
treatment of AR (14). The role of histamines in allergic 
diseases is different in each individual, and it depends 
on the gene expression or polymorphisms involved in 
the pathogenesis of AR (15). Studies on the role of 
antihistamines in the expression of the genetic varia-
tion in AR have been limited. The main goal of this 
paper was to discuss the effects of H1-antihistamines 
on the IL and TLR systems in AR.
DISCUSSION
Activation and inactivation models of 
H1-histamine receptors
H1-histamine receptors in humans are members 
of the superfamily of G-protein-coupled receptors 
(GPCRs). This superfamily consists of approximately 
500 membrane proteins that have seven transmem-
brane α-helix structural motifs. The H1-histamine 
receptor gene encodes the 487-amino-acid protein 
with a predicted molecular mass of 55.8 kilodaltons 
(kDa). The absence of introns in the H1-histamine 
receptor gene indicates that only the transcription of 
the single receptor protein encoding gene occurs (16).
Similarly to other G-protein receptors, the 
H1-histamine receptors have an important role 
in cellular activation and inactivation. Histamines 
cross-link areas on the III and V trans membrane 
domains, which leads to the receptor activation. 
H1-antihistamines are non-structural compounds 
that are not necessarily antagonists to the histamine 
binding, but they can bind to a different site on the 
histamine receptors to produce the opposite effect 
of histamines. For example, cetirizine cross-links the 
IV and VI trans membrane domains to stabilize the 
receptor in its inactive state. Therefore, it does not 
function as the H1-histamine receptor antagonist, 
but as the inverse agonist to produce the opposite 
effect of histamines (16). This process is illustrated 
in Figure 1.
H1-antihistamines in interleukin system
H1-antihistamines are not the receptor antago-
nists, but inverse agonists. The basic structure of 
H1-antihistamines consist of two aromatic rings 
connected with ethylamine (17). If the amount of 
H1-histamines and H1-antihistamines is equal, the 
H1-histamine receptors are in the balance state. 
The histamines are associated with the activation 
of the H1-histamine receptors and cellular stimu-
lation, while the antihistamines are associated with 
their inactivation. Therefore, histamine  -  induced 
cell or tissue stimulation depends on the balance 
between the histamines and antihistamines (18).
The H1-histamine receptors have different effects 
on the immune system, including dendritic cells 
maturation and modulation of the balance of 
Type 1 and 2 helper T (Th1 and Th2) cells. The his-
tamines also induce the release of proinflammatory 
cytokines. Therefore, H1-antihistamines can reduce 
the proinflammatory cell expression and accumula-
tion of eosinophils and neutrophils (18). It has been 
showed that the expression of the H1-histamine 
receptor affects the severity of AR and that the 
expression of the H1-histamine receptor messenger 
ribonucleic acid (mRNA) in AR is increased  (9). 
In addition, upregulation of the H1-histamine 
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receptor can be induced by ILs through the acti-
vation of the H1-histamine receptor gene (19) and 
histidine decarboxylase (HDC) gene transcription 
(Figure  2) (20). The role of ILs in regulating the 
mRNA expression of the H1-histamine receptor was 
demonstrated by Shahriar et al. (21) using a mouse 
model. The mice were injected with IL-4 which 
resulted in the upregulation of the H1-histamine 
receptor mRNA.
Several studies reported the association of AR with 
IL-4 gene polymorphisms in ethnically and geo-
graphically distinct populations. The contribution 
of these genes to AR pathogenesis was analyzed by 
Movahedi et al. (22) in Iranian patients with AR. 
This study analyzed IL-4 gene polymorphisms in 
the AR patients. The results showed that IL-4 was 
associated with AR and had a role in the devel-
opment of AR clinical manifestation. They also 
FIGURE 1. Model of the H1-histamine receptor. A) The structure of the H1-histamine receptor (16). B) The H1-histamine receptors have 
2 conformational states. C) Histamines act as agonists to activate the H1-histamine receptor. D) Antihistamines act as inverse agonists to 
inactivate the H1-histamine receptor (17). E) The H1-histamine receptor surface is connected to the III and V transmembrane domains to 
activate and F) to the IV and VI transmembrane domains to inactivate of H1-histamine receptor [adapted with permission from reference 16].
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found that the C allele of the reference sequence 
rs2243250 of the IL-4 gene was significantly 
overrepresented in the AR patients. On contrary, 
rs2243248, rs2243250, and rs2070874 haplotypes 
of the IL-4 gene had a significant negative correla-
tion with AR. In other study, Bottema et al. (23) 
analyzed IL-13 and IL-4 polymorphisms in AR and 
asthma patients in the Netherland. They showed 
that IL-13 C–1111T (rs1800925) polymorphism 
was significantly associated with rhinitis and atopic 
phenotypes in AR patients, but was not associated 
with asthma. IL-13 Arg130Gln (rs20541) and 
G870A (rs1295685) polymorphisms had a sig-
nificant association with asthma and serum IgE. 
IL-4R Glu375Ala (rs1805011) and Ser411Leu 
(rs1805013) polymorphisms were also associated 
with asthma. IL-4RA Gln551Arg (rs1801275) poly-
morphism was associated with AR susceptibility in 
Asian, but  IL-4RA Ile50 Val as well as Ser478Pro 
polymorphisms were not associated with AR sus-
ceptibility both in Asian and Caucasian. In addi-
tion, genotypes combination of  IL-13  Arg130Gln 
with  IL-4R  Glu375Ala, and  IL-13  C–1111T 
with IL4R Ser478Pro were associated with increased 
risks for asthma (24). Another study conducted by 
Walley & Cookson (25) investigated the association 
of IL-4 gene polymorphisms with atopic diseases, 
including AR. They found that the rs2243250 vari-
ant among IL-4 polymorphisms was associated with 
atopic diseases. Another study conducted in Canada 
by Zhu et al. (26) investigated the association of 
IL-4, tumor necrosis factor (TNF-  α), and Fc α 
RI β gene polymorphisms with the risk of allergic 
disorders in infants. They showed that IL-4-589*T 
(rs2243250) variant, but not TNF-  α  -308*2 or 
Fc α RI β *G variants, was associated with the 
risk factor for the development of atopy, asthma, 
and rhinitis by 12 months of age. Furthermore, a 
study conducted in Pakistan by Michael et al. (27) 
analyzed the association of IL-4 gene polymor-
phisms with the risk of atopic asthma and AR in 
Pakistani patients. They found that rs2243250 and 
rs2227284 single-nucleotide polymophisms (SNPs) 
had a significant association with the risk of asthma 
and AR. Li et al. (28) conducted a meta-analysis on 
IL-4 gene polymorphisms in AR. They showed that 
TABLE 1. Interleukin gene polymorphisms associated with AR susceptibility in different populations
IL IL gene polymorphisms Populations References
IL-4 rs2243250 Iranian, Pakistani, 
Australian, Canada
Movahedi et al (22); Michael et al (27); Walley & Cookson (25); 
Zhu et al. (26); Li et al (28)
rs1800925 Netherland Bottema et al (23)
rs1801275 - Xu & Zhang (24)
rs2227284 Pakistani Michael et al (27)
rs2070874 - Li et al (28)
IL-6 rs1800795 Iranian Nasiri et al (29)
rs1800797 Iranian Nasiri et al (29)
IL-10 rs1800871 Iranian Nasiri et al (30)
rs1800872 Iranian Nasiri et al (30)
IL-12R rs438421 Chinese Wei et al (31)
IL-13 rs1800925 Netherland Bottema et al (23)
rs20541 Asian, Malaysian Yadav et al (32); Ying et al (33); Andiappan et al (34) 
IL-17 rs3819024 Chinese Wang et al (35)
IL-18 rs360721 Germany Kruse et al (36)
rs360718 Germany Kruse et al (36)
rs360717 Germany Kruse et al (36)
rs187238 Germany Kruse et al (36)
IL-23R rs7517847 Chinese Hu et al (37)
IL-27 rs153109 Chinese Shen et al (38)
rs17855750 Chinese Shen et al (38)
IL=Interleukin, rs=Reference sequence
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C-590T (rs2243250) and C-33T (rs2227284) poly-
morphisms had a significant association with AR. 
Data on the interleukin genes polymorphisms asso-
ciated with AR susceptibility are listed in Table 1.
Several other studies reported the correlation of 
polymorphisms of IL-6, IL-10, IL-12, IL-13, IL-17, 
IL-18, IL-23, and IL-27 genes with susceptibility 
to AR. Nasiri et al. (29) analyzed the association 
of IL-6 SNPs with the risk of AR. They found that 
rs1800795 and rs1800797 variants of IL-6 gene had 
a significant association with the increased risk of 
developing AR. Nasiri et al. (30) also analyzed the 
association of gene polymorphisms in IL-10 and 
transforming growth factor β (TGF-β) genes with 
AR. They found that rs1800896 variant of IL-10 
gene and rs1982037 variant of TGF-β gene were sig-
nificantly less frequent in AR, while rs1800471 vari-
ant of TGF-β gene and rs1800871 and rs1800872 
variants of IL-10 gene were associated with higher 
susceptibility to AR. Another study conducted in 
Chinese Han population by Wei et al. (31) analyzed 
the association between IL-12Rβ1/β2 genes and 
AR. They showed that rs438421 polymorphism in 
IL-12Rβ1 gene had a significant association with 
AR. In addition, rs1800925 polymorphism in IL-13 
gene showed a significant association with AR sus-
ceptibility in Netherland population (23). In other 
study conducted in Malaysian population, Yadav 
et al. (32) investigated the polymorphic variants 
of IL-13 R130Q, IL-4 T589C, IL-4 RAI50V, and 
IL-4 RAQ576R genes in AR patients. They found 
that IL-13 R130Q (rs20541) polymorphism had a 
significant association with increased risk for devel-
opment of AR, but not IL-4 T589C, IL-4RA 150V, 
and IL-4RA Q576 polymorphisms. In addition, 
rs20541 variant in IL-13 gene was shown to be 
associated with AR susceptibility by Ying et al. (33) 
and Andiappan et al. (34). A  study conducted in 
Chinese population by Wang et al. (35) investigated 
the association of IL-17A and IL-17F gene polymor-
phisms with the development of AR. They found 
that rs3819024 SNP was potentially associated 
with AR. Another study, conducted in Germany 
by Kruse et al. (36), analyzed the association of 
IL-18 (–920[t/c], –133[c/g], and –132[a/g] in pro-
moter 2 upstream of exon 2; +179[c/a; Ser35Ser] 
in exon 4; and +486[c/t; Phe137Phe] in exon 6) 
polymorphisms with AR. They found that the SNPs 
–133[c/g] (rs360721) had significant association 
with high serum IgE levels and specific sensitization 
to common allergens. The SNPs in exon 1 +113[t/g] 
(rs360718) and +127[c/t] (rs360717) and in pro-
moter 1 –137[g/c] (rs187238) of the IL18 gene also 
had significant association with high IgE levels and 
specific sensitization. Other study, conducted by 
Hu et al. (37), analyzed the association of IL-23R 
gene polymorphisms with AR. They showed that 
rs7517847 variant of IL-23R gene had a strong 
association with AR susceptibility. A Study by Shen 
et al. (38) investigated the association of IL-27 gene 
polymorphisms with the risk of AR. They found 
that rs153109 and rs17855750 polymorphisms in 
IL-27 gene were involved in AR susceptibility. Based 
on these data, we can conclude that the variation 
in the expression of the IL genes has an important 
role in the pathogenesis of AR. As the result, the 
supression of the transcription of the IL genes could 
reduce the clinical manifestations of AR.
H1-antihistamines inhibit the up-regulation of the 
H1-histamine receptor gene expression and suppress 
histamine basal signaling through the inverse agonis-
tic activity (9). A study by Lippert et al. (39) exam-
ined the role of H1-antihistamines in allergic dis-
eases. They showed that H1-antihistamines inhibit 
the cytokine secretion in mast cells. In addition, 
Shahriar et al. (21) showed that the down-regulation 
of the H1-histamine receptor gene expression by 
the antihistamines occurs through the transcription 
suppression of HDC and IL-4 genes (Figure 2). The 
role of antihistamines in the IL-4 gene suppression 
has also been studied by Mizuguchi et al. (40). The 
decrease of IL-4 in AR after H1-antihistamine treat-
ment has been demonstrated by Testa et al.  (11). 
A study conducted by Masamoto et al. (41) exam-
ined IL-4 cytokines in patients with AR. They 
showed that IL-4 and vascular cell adhesion protein 
1 (VCAM-1) were increased significantly. Wang 
et al. (42) conducted a study on the association of 
histamines and IL-6 expression. They showed that 
histamines could stimulate the release of IL-6. Thus, 
the development of H1-antagonist that inhibits the 
release of IL-6 could be an efficient treatment for dis-
ease with elevated levels of histamines. Another study 
conducted by Osna et al. (43) analyzed the regula-
tion of IL-10 secretion by histamines. They showed 
that histamines could stimulate IL-10 production 
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in Th2  cells which is reversed by both H1-  and 
H2-  receptor antagonists and by protein kinase A 
(PKA) inhibitors H8 and rp-adenosine-3’,5’-cyclic 
monophosphothionate (Rp-cAMPS). Therefore, 
inhibition of histamine could suppress IL-10 pro-
duction. Other study by Elenkov et al. (44) showed 
that histamine increased the production of IL-10 in 
lipopolysaccharide (LPS)-stimulated whole blood 
cultures. A  study conducted by Elliott et al. (45) 
investigated the regulation of IL-13 production by 
histamines in cloned murine Th2 cells. They found 
that histamines could stimulate the IL-13 secretion 
and transcription through PKA and Janus kinase/
signal transducer and activator of transcription 
(JAK-STAT) pathway. Based on these data, hista-
mines trigger the production of IL through several 
mechanisms, including: (1) histamines stimulate the 
IL production in Th2 cells which is reversed by both 
H1- and H2- receptor antagonists, PKA inhibitors 
H8, and Rp-cAMPS (43), (2) histamines stimulate 
the IL secretion and transcription through PKA 
and JAK-STAT pathway (45), (3) histamines stim-
ulate the IL production through the transcription 
activation of the H1-histamine receptor (19) and 
HDC genes (20). On contrary, the mechanisms of 
antihistamines in IL system through several path-
ways, i.e.  (1) antihistamines inhibit the up-regula-
tion of the H1-histamine receptor gene expression 
and suppress histamine basal signaling through the 
inverse agonistic activity (9), (2) antihistamines 
inhibit the cytokine secretion in mast cells (39), (3) 
antihistamines down-regulate the H1-histamine 
receptor gene expression by suppressing the tran-
scription of HDC and IL genes (21). Thus, the inhi-
bition of histamines possibly inhibits the production 
of IL which plays an important role in the pathogen-
esis of AR. Several studies have shown the associa-
tion of antihistamines with the plasma levels of ILs. 
Crisan et al. (46) conducted a study on the effect 
of H1-antihistamine therapy on cytokine profile in 
patients with chronic urticaria. They showed that 
H1-antihistamines significantly reduced the plasma 
levels of IL-1β, IL-2, IL-4, IL-6, IL-17, and IL-31. 
Elevated levels of histamines have an important role 
in the pathogenesis of AR and urticaria. So, it is pos-
sible that this process also occurs in AR. A study con-
ducted by Boscan et al. (47) also analyzed the effects 
of H1-antihistamines in AR. They showed that 
H1-antihistamines could reduce the plasma levels of 
IL-1β, IL-6, and IL-8 after a four-week treatment.
H1-antihistamines in toll like receptor system
The inflammatory process involving intracellu-
lar adhesion molecule 1 (ICAM-1) in nasal epi-
thelial cells has an important role in AR patho-
genesis. This process is stimulated by TLR3. The 
TLR3 expression is modulated by histamines (48). 
TLR3-mediated signaling pathways are induced by 
myeloid differentiation factor 88 (MyD88) adapt-
ers and TIR-domain-containing adaptor protein 
inducing IFN-β (TRIF) or Toll-like receptor adap-
tor molecule 1 (TICAM-1). This process induces 
the response of interferon -β (IFN-β) and the acti-
vation of nuclear factor-kappa B (NF-kB) and c-Jun 
N-terminal kinase (JNK). The C and N terminal 
regions of TRIF activate NF-kB through a differ-
ent mechanism. The N terminal region of TRIF 
activates NF-kB through TNF receptor associated 
factor 6 (TRAF6). Another mechanism for the 
NF-kB activation is the interaction between homo-
tipic receptor – interacting protein (RIP) with the 
RIP homotypic interaction motif (RHIM) domain 
in the C terminal of TRIF which attracts RIP1 
serine threonine kinase to induce the activation of 
NF-kB (49).
FIGURE 2. The pathway of histamine synthesis stimulation 
and inverse agonist through histidine decarboxylase (HDC). 
Up-regulation of H1-histamine receptor is induced by IL-4 through 
the activation of H1-histamine receptor genes and histidine decar-
boxylase gene. Antihistamines has a mechanism to inhibit the 
up-regulation of H1-histamine gene expression and suppress 
histamine basal signal through inverse agonistic activity. Down-
regulation of H1-histamine gene expression by antihistamines 
occurs through suppression of histidine decarboxylase and IL-4 
gene transcription.
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Besides TLR3, histamines also induce other TLRs to 
stimulate the inflammation in endothelial cells (50) 
(Figure 3). The role of histamines in inducing the 
expression of TLR2 and TLR4 in endothelial cells 
was described by Stechschulte et al. (51). They 
showed that histamines had an important role in the 
mRNA and protein expression of TLR2 and TLR4. 
Histamines are inflammatory molecules released by 
mast cells and have been shown to activate endothe-
lial cells. The role of TLR2 and TLR4 in the activa-
tion of mast cells was investigated by Varadaradjalou 
et al. (52). They described that the mast cell activa-
tion by TLR2 and TLR4 caused mast cells to pro-
duce TNF-α, IL-5, IL-10, and IL-13. Other study 
conducted by Greiff et al. (53) analyzed the TLR7 
stimulation in AR. They found that TLR stimula-
tion by AZD8848, a TLR7 agonist, was responsible 
for allergen sensitization in AR. A study conducted 
by Fransson et al. (54) investigated the upregulation 
of TLR2, TLR3, and TLR4 in AR. They found that 
the increase of the mRNA and protein expression 
of TLR2, TLR3, and TLR4 had a significant asso-
ciation with AR, and the highest increase of mRNA 
was in the TLR3. Another study by Fransson 
et al. (55) analyzed the expression of TLR9 in AR 
patients. They found that the widespread expression 
of TLR9 was associated with AR. A study in a mouse 
model by Zhang et al. (56) analyzed the association 
of TLRs and NF-kB with AR. They found that AR 
could upregulate the levels of TLR4 an NF-kB and 
stimulate the infiltration of eosinophils and the 
expression of IgE. Cui et al.  (57) also investigated 
the expression of TLRs in AR. They found that the 
mRNA expression of TLR2 and TLR4 was signifi-
cantly higher in patients with AR. In addition, the 
mRNA expression of IL-6 and IL-8, but not IL-1, 
FIGURE 3. TLR signaling pathways. TLR signals trigger the activation of transcription factors, including interferon regulatory factors 
(IRFs) and NF-kB, which are required for the transcription of inflammatory genes. Except for TLR3, all types of TLRs attract MyD88 to trig-
ger downstream signaling, resulting in the activation of NF-kB. Whereas NF-kB activation by TLR3 occures through the TRIF dependent 
pathways. IRAK: IL-1 receptor-associated kinases; MAL: MyD88-adaptor like; MyD88: Myeloid differentiation protein 88; TLR: Toll-like 
receptor; TRAF: Tumour necrosis factor receptor-associated factor 6; TRAM: TRIF-related adaptor molecule; TRIF: TIR domain-contain-
ing adaptor inducing interferon-β [adapted with permission from reference 50].
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IL-12, IFN-α, and TNF-α, was upregulated in 
patients with AR. They concluded that TLR2 and 
TLR4 were increased in patients with AR and could 
be one of the major contributors to the persistence 
and aggravation of allergic inflammation in AR. 
Furthermore, Okumura et al. (58) explained that 
TLR4 plays an important role in the specific gene 
expression in mast cells. They also showed that the 
expression of TLR4 occurred when mast cells were 
up-regulated by IFN-γ. Thus, the inhibition of his-
tamines causes the disruption of TLR2 and TLR4 
expression. Therefore, antihistamines are possible to 
cause disturbance of mast cell gene expression pro-
file to cause inflammation.
Several studies have also reported the association 
of AR with TLR gene polymorphisms in ethni-
cally and geographically distinct populations. The 
contribution of these genes to AR pathogenesis 
was analyzed by Hussein at al. (10) in Egyptian 
patients with AR. This study analyzed the associa-
tion of TLR2 and TLR4 gene polymorphisms with 
asthma and AR. They found that the allele frequen-
cies of TLR2 Arg753Gln (rs5743708) and TLR4 
Asp299Gly (rs4986790) polymorphisms were not 
significantly different between asthmatic or AR chil-
dren compared to the controls. However, a signifi-
cant association between these genetic variants and 
the severity of the diseases was suggested. In other 
study, Qian et al. (59) investigated the association 
of polymorphisms in TLR2 subfamily with the risk 
of asthma and AR in Chinese population. They 
found that rs11466651 variant of TLR10 gene was 
negatively associated with AR, and rs7656411 poly-
morphism of TLR2 gene had a significantly reduced 
risk of asthma. On contrary, rs2381289 polymor-
phism of TLR6 gene was significantly associated 
with AR and asthma. Another study, conducted by 
Nilsson et al. (60), investigated 73 SNPs in TLR7 
and TLR8 genes in AR. They found that SNPs 
rs2407992, rs17256081, and rs5741883 in TLR8 
and rs5935438 in TLR7 had significant association 
with AR in Swedish population. They also found 
that SNPs rs2407992, rs4830805, rs17256081, 
rs3788935, and rs178998 in TLR8 gene had a sig-
nificant association with AR in Chinese population. 
Furthermore, a study conducted by Gao et al. (61) 
analyzed TLR gene polymorphisms in AR. They 
found that rs4696480 variant (German and Austrian 
population) and rs3804099 variant (Korean popu-
lation) of TLR2 gene, rs4986790 variant of TLR4 
gene (Canadian population), rs2381289 variant of 
TLR6 gene and rs11466651 variant of TLR10 gene 
(Chinese population), rs179008 variant of TLR7 
gene (Danish population), as well as rs2407992 and 
rs5741883 variants of TLR8 gene (Danish popu-
lation) had a significant association with AR sus-
ceptibility. Data on the TLR gene polymorphisms 
associated with AR susceptibility is listed in Table 2.
Antihistamines have the mechanism to suppress 
TRIF and RIP proteins, as the result, this inhibits 
TABLE 2. TLR genes polymorphisms associated with AR susceptibility in different populations
TLR TLR genes polymorphisms Population References
TLR2 rs4696480 Germany, Austrian Gao et al (61)
rs3804099 Korean Gao et al (61)
rs5743708 Egyptian Hussein at al (10)
TLR4 rs4986790 Canadian, Egyptian Gao et al (61); Hussein at al (10)
TLR6 rs2381289 Chinese Gao et al (61); Qian et al (59)
TLR7 rs179008 Danish Gao et al (61)
rs5935438 Swedish Nilsson et al (60)
TLR8 rs2407992 Danish, Swedish, Chinese Gao et al (61); Nilsson et al (60)
rs5741883 Danish, Swedish Gao et al (61); Nilsson et al (60)
rs17256081 Swedish, Chinese Nilsson et al (60)
rs4830805 Chinese Nilsson et al (60)
rs3788935 Chinese Nilsson et al (60)
rs178998 Chinese Nilsson et al (60)
TLR10 rs11466651 Chinese Gao et al (61); Qian et al (59)
IL=Interleukin, rs=Reference sequence
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the expression of TLR and the inflammatory pro-
cess in nasal epithelial cells (48). Study by Kaiser 
et al. (62) reported that TRIF and RIP proteins 
were essential for the TLR activation. Other study 
by Cusson-Hermance et al. (63) suggested that RIP 
use ubiquitin-dependent mechanism to activate IκB 
kinase-β in response to TNF-α and TLR ligands. 
Study by Meylan et al. (49) revealed that RIP was 
essential mediator in the TLR-induced NF-Kβ acti-
vation. The correlation between the TLR expression 
and histamine treatment has been reported. Jang 
et al. (64) analyzed the expression of TLRs stimu-
lated by histamine in cultured human skin fibro-
blast. They found that the expression of TLRs 2, 
3, 6, 7, 8, and 9 was decreased after six hours of 
the histamine treatment. Among the TLRs with the 
decreasing expression pattern, TLRs 7 and 8 showed 
a persistent tendency to decrease. Interestingly, ther-
apy that has a target site in the TLR system recently 
has been shown to have better benefits. Study by 
Creticos et al (65) showed that the AIC vaccine, 
AR vaccine, has a target site in the TLR system, has 
a good efficacy to cope AR. Based on these data, 
histamines trigger the TLR expression through sev-
eral mechanisms, including: (1) stimulating IFN-γ 
to up-regulate mast cells (58), (2) stimulating RIP 
through the ubiquitin-dependent mechanism to 
activate IκB kinase-β. On contrary, antihistamines 
suppress TRIF and RIP proteins and thus inhibit 
the expression of TLR (48).
CONCLUSION
In the IL system, histamines trigger the IL produc-
tion in Th2 cells, which is reversed by both H1- and 
H2- receptor antagonists, PKA inhibitors H8, and 
Rp-cAMPS through PKA, JAK-STAT pathway, and 
the activation of H1-histamine receptor gene and 
HDC gene transcription. On contrary, antihista-
mines inhibit or down-regulate the H1-histamine 
receptor gene expression through the suppression of 
HDC and IL gene transcription and suppress hista-
mine basal signaling through the inverse agonistic 
activity. In the TLR system, histamines trigger the 
TLR expression by stimulating IFN-γ to up-regu-
late mast cells and by stimulating RIP through the 
ubiquitin-dependent mechanism to activate IκB 
kinase-β. In addition, antihistamines suppress TRIF 
and RIP proteins and inhibit the expression of TLR.
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